ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Syndax Pharmaceuticals, Inc. ?
1
Poor Management Efficiency with a low ROE of 0.83%
- The company has been able to generate a Return on Equity (avg) of 0.83% signifying low profitability per unit of shareholders funds
2
With a growth in Net Sales of 223.64%, the company declared Very Positive results in Mar 26
- NET SALES(Q) At USD 64.86 MM has Grown at 223.64%
- OPERATING PROFIT MARGIN(Q) Highest at -52.72 %
- RAW MATERIAL COST(Y) Fallen by -0.37% (YoY)
3
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 113.38%, its profits have risen by 10.5%
4
High Institutional Holdings at 100%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
5
Market Beating Performance
- The stock has generated a return of 113.38% in the last 1 year, much higher than market (S&P 500) returns of 22.24%
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Syndax Pharmaceuticals, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Syndax Pharmaceuticals, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Syndax Pharmaceuticals, Inc.
116.7%
-0.01
57.84%
S&P 500
20.78%
1.67
13.28%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
157.66%
EBIT Growth (5y)
-212.73%
EBIT to Interest (avg)
-75.64
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.78
Sales to Capital Employed (avg)
0.14
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0.83%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
32.06
EV to EBIT
-7.41
EV to EBITDA
-7.41
EV to Capital Employed
135.34
EV to Sales
11.72
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-1826.10%
ROE (Latest)
-441.62%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
Mildly Bullish
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend26What is working for the Company
NET SALES(Q)
At USD 64.86 MM has Grown at 223.64%
OPERATING PROFIT MARGIN(Q)
Highest at -52.72 %
RAW MATERIAL COST(Y)
Fallen by -0.37% (YoY
INVENTORY TURNOVER RATIO(HY)
Highest at 0.44 times
DEBTORS TURNOVER RATIO(HY)
Highest at 5.29 times
OPERATING PROFIT(Q)
Highest at USD -34.2 MM
PRE-TAX PROFIT(Q)
Highest at USD -42.67 MM
NET PROFIT(Q)
Highest at USD -42.67 MM
EPS(Q)
Highest at USD -0.48
-15What is not working for the Company
ROCE(HY)
Lowest at -189.53%
DEBT-EQUITY RATIO
(HY)
Highest at -16.11 %
INTEREST(Q)
Highest at USD 11.85 MM
Here's what is working for Syndax Pharmaceuticals, Inc.
Net Sales
At USD 64.86 MM has Grown at 223.64%
Year on Year (YoY)MOJO Watch
Near term sales trend is extremely positive
Net Sales (USD MM)
Operating Profit Margin
Highest at -52.72 % and Grown
In each period in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Operating Profit
Highest at USD -34.2 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (USD MM)
Pre-Tax Profit
Highest at USD -42.67 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
Highest at USD -42.67 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
EPS
Highest at USD -0.48
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Inventory Turnover Ratio
Highest at 0.44 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its inventory faster
Inventory Turnover Ratio
Debtors Turnover Ratio
Highest at 5.29 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Raw Material Cost
Fallen by -0.37% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Syndax Pharmaceuticals, Inc.
Interest
At USD 11.85 MM has Grown at 23.49%
period on period (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (USD MM)
Interest
Highest at USD 11.85 MM
in the last five periods and Increased by 23.49% (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (USD MM)
Debt-Equity Ratio
Highest at -16.11 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
